Syndax Pharmaceuticals (NASDAQ:SNDX) Lowered to “Sell” Rating by Wall Street Zen

Wall Street Zen downgraded shares of Syndax Pharmaceuticals (NASDAQ:SNDX) from a hold rating to a sell rating in a research report report published on Saturday morning.

A number of other research analysts have also recently weighed in on SNDX. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Syndax Pharmaceuticals in a report on Monday, December 29th. BTIG Research restated a “buy” rating and set a $56.00 target price on shares of Syndax Pharmaceuticals in a research report on Tuesday, December 9th. Barclays upped their price target on Syndax Pharmaceuticals from $22.00 to $35.00 and gave the stock an “overweight” rating in a report on Monday, November 24th. Stifel Nicolaus set a $45.00 price objective on Syndax Pharmaceuticals in a report on Friday. Finally, JPMorgan Chase & Co. cut their price objective on Syndax Pharmaceuticals from $40.00 to $33.00 and set an “overweight” rating for the company in a research report on Wednesday, November 12th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Syndax Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $37.30.

Syndax Pharmaceuticals Trading Up 5.0%

Shares of NASDAQ:SNDX opened at $21.71 on Friday. The company has a current ratio of 4.64, a quick ratio of 4.42 and a debt-to-equity ratio of 2.78. Syndax Pharmaceuticals has a 12-month low of $8.58 and a 12-month high of $22.73. The business has a 50 day moving average of $20.86 and a two-hundred day moving average of $18.03. The company has a market capitalization of $1.89 billion, a PE ratio of -6.60 and a beta of 0.46.

Syndax Pharmaceuticals (NASDAQ:SNDX) last posted its earnings results on Monday, March 2nd. The company reported ($0.78) earnings per share for the quarter, missing the consensus estimate of ($0.66) by ($0.12). Syndax Pharmaceuticals had a negative net margin of 165.37% and a negative return on equity of 175.50%. The firm had revenue of $68.73 million for the quarter. During the same period last year, the business posted ($1.10) earnings per share. Syndax Pharmaceuticals’s quarterly revenue was up 792.6% on a year-over-year basis. As a group, analysts forecast that Syndax Pharmaceuticals will post -3.72 EPS for the current year.

Insider Buying and Selling

In other Syndax Pharmaceuticals news, CEO Michael A. Metzger sold 17,159 shares of the firm’s stock in a transaction on Monday, February 9th. The stock was sold at an average price of $21.03, for a total value of $360,853.77. Following the transaction, the chief executive officer owned 491,690 shares in the company, valued at approximately $10,340,240.70. This trade represents a 3.37% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Keith A. Goldan sold 3,410 shares of Syndax Pharmaceuticals stock in a transaction on Monday, February 9th. The stock was sold at an average price of $21.03, for a total transaction of $71,712.30. Following the sale, the chief financial officer directly owned 140,429 shares in the company, valued at approximately $2,953,221.87. This trade represents a 2.37% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 30,063 shares of company stock worth $628,332 over the last ninety days. Corporate insiders own 4.10% of the company’s stock.

Institutional Trading of Syndax Pharmaceuticals

A number of hedge funds have recently bought and sold shares of SNDX. Smartleaf Asset Management LLC boosted its holdings in shares of Syndax Pharmaceuticals by 2,698.9% during the 4th quarter. Smartleaf Asset Management LLC now owns 2,659 shares of the company’s stock worth $55,000 after purchasing an additional 2,564 shares during the last quarter. Larson Financial Group LLC increased its holdings in shares of Syndax Pharmaceuticals by 192.2% in the third quarter. Larson Financial Group LLC now owns 2,922 shares of the company’s stock valued at $45,000 after purchasing an additional 1,922 shares during the last quarter. Quantbot Technologies LP purchased a new position in Syndax Pharmaceuticals during the third quarter worth approximately $53,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in Syndax Pharmaceuticals by 26.8% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,223 shares of the company’s stock worth $89,000 after buying an additional 893 shares during the last quarter. Finally, Lazard Asset Management LLC purchased a new stake in Syndax Pharmaceuticals in the 2nd quarter valued at $66,000.

Key Syndax Pharmaceuticals News

Here are the key news stories impacting Syndax Pharmaceuticals this week:

• Positive Sentiment: Robust commercial revenue — Syndax reported $68.7M in Q425 and $172.4M for FY2025, driven by product sales; Revuforj (revumenib) net revenue was $44.2M in Q4 (up 38% vs Q3) and Niktimvo (axatilimab‑csfr) net revenue was $56.0M in Q4 (up 22% vs Q3). Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
• Positive Sentiment: Revenue topped expectations and showed large year‑over‑year growth (Q4 revenue up ~792% YoY), which investors may view as validation of the commercialization ramp. Syndax Pharmaceuticals Inc (SNDX) Q4 2025 Earnings Call Highlights
• Positive Sentiment: Clinical progress: enrollment completed in the Phase 2 IPF trial of axatilimab with topline data expected in 4Q26 — a clear near‑to‑mid‑term catalyst to monitor. Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
• Neutral Sentiment: Analyst consensus remains constructive — the stock carries an average rating of “Moderate Buy,” which may support sentiment but is not a new catalyst by itself. Syndax Pharmaceuticals, Inc. Receives Average Rating of “Moderate Buy” from Analysts
• Neutral Sentiment: Company hosted an earnings conference call and published slides; these materials provide additional detail on commercialization cadence and guidance drivers. View Press Release / Slide Deck
• Negative Sentiment: EPS missed estimates — Syndax reported a Q4 loss of $0.78 per share versus consensus around ($0.64)–($0.66), signaling continued losses and pressure on near‑term profitability. Syndax Pharmaceuticals (SNDX) Reports Q4 Loss, Tops Revenue Estimates
• Negative Sentiment: Profitability metrics remain weak — the company reported a negative net margin and negative return on equity, underscoring that top‑line growth has yet to translate into earnings. Syndax Q4 Earnings Snapshot / Conference Call

About Syndax Pharmaceuticals

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for the treatment of cancer. Headquartered in Waltham, Massachusetts, the company focuses on small-molecule inhibitors that target key epigenetic and protein interaction pathways. Syndax’s research platform aims to enhance the effectiveness of existing therapies and address high unmet medical needs in oncology.

The company’s lead investigational candidate, entinostat, is a selective class I histone deacetylase (HDAC) inhibitor being evaluated for multiple solid tumor and hematologic indications.